Nucleotide Regulation of Apaf-1 Apoptosome and Apoptosis
Apaf-1 凋亡体和细胞凋亡的核苷酸调控
基本信息
- 批准号:7301458
- 负责人:
- 金额:$ 33.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAffectApoptosisApoptoticAppendixBindingBiochemicalBioenergeticsBiologicalCarcinogensCaspaseCell DeathCellsCessation of lifeDefectDevelopmentEnvironmental CarcinogensEnvironmental HazardsEventGoalsIn VitroLeadMaintenanceMammalian CellMediatingMetabolismMicroinjectionsMitochondriaMolecularNucleic AcidsNucleotidesPathway interactionsPharmaceutical PreparationsPhysiologicalProtein IsoformsRadiationRegulationResearch PersonnelResistanceRoleStimulusStressTherapeuticTreatment Protocolsanti-cancer therapeuticapoptotic protease-activating factor 1cancer cellcaspase-3caspase-9cytochrome chazardin vivoneoplasticneoplastic cellpreventprogramsreconstitutionresponsetumor
项目摘要
DESCRIPTION (provided by applicant): Environmental hazards and stress, carcinogens, and anti-cancer therapeutics cause apoptotic cell death through the intrinsic or mitochondrial death pathway. Abnormal apoptotic response often contributes to tumor development and defects in apoptosis are intimately associated with tumor cell resistance to anti- neoplastic agents. Caspase activation lies in the core of apoptotic cell death. In the mitochondrial death pathway, cytochrome c (CC)-initiated Apaf-1 apoptosome formation represents a key initiating event in caspase-9 (an initiator caspase) activation, which ultimately activates effector caspases such as caspase-3 to execute cell demise. How Apaf-1 apoptosome is formed and regulated in vivo (i.e., in the stimulated cells) remains poorly understood. Recently, we provided evidence that physiological levels of nucleotides inhibit the CC-induced, apoptosome-mediated caspase-9 activation by binding directly to CC and preventing CC from interacting with Apaf-1 (Chandra et al., Cell 125, 1333-1346, 2006; Appendix I). Consequently, the CC- mediated apoptosome assembly and activation are blocked. Co-microinjection of nucleotides and CC renders cells resistant to the CC-induced apoptosis in vivo whereas experimentally reducing nucleotides enhances both CC and apoptotic stimuli-induced cell death. These observations lead us to hypothesize that physiological levels of nucleotides, in addition to their well-established roles in nucleic acid synthesis, intermediate metabolism, and maintenance of bioenergetics, also function as critical prosurvival factors by directly inhibiting the CC-mediated apoptosome formation and caspase activation. There are several critical unanswered questions related to Apaf-1 apoptosome regulation by nucleotides. We propose the following three Specific Aims to address some of these questions: 1) To further study nucleotide interaction with CC in vitro and to elucidate nucleotide interaction with CC in vivo; 2) To investigate nucleotide interaction with Apaf-1 and its impact on apoptosome activation; and 3) To study the effects of Apaf-1 isoform expression and nucleotide interaction on Apaf-1 apoptosome activation. These goals will be achieved by a combination of cell biological, biochemical, and molecular approaches. The accomplishment of the proposed goals will greatly advance our understanding of apoptosome regulation in vivo and help us understand cellular response to environmental stress and cancer cell response to anti- tumor therapeutics.
描述(由申请人提供):环境危害和压力、致癌物和抗癌治疗剂通过内在或线粒体死亡途径引起细胞凋亡。异常的细胞凋亡反应通常促进肿瘤的发展,并且细胞凋亡中的缺陷与肿瘤细胞对抗肿瘤剂的抗性密切相关。Caspase的激活是细胞凋亡的核心。在线粒体死亡途径中,细胞色素c(CC)启动的Apaf-1溶酶体形成代表了半胱天冬酶-9(引发剂半胱天冬酶)活化中的关键起始事件,其最终激活效应半胱天冬酶如半胱天冬酶-3以执行细胞死亡。Apaf-1核糖体如何在体内形成和调节(即,在受刺激的细胞中)仍然知之甚少。最近,我们提供的证据表明,生理水平的核苷酸通过直接结合CC并阻止CC与Apaf-1相互作用来抑制CC诱导的、溶酶体介导的胱天蛋白酶-9活化(Chandra等人,Cell 125,1333-1346,2006;附录I)。因此,CC介导的溶酶体组装和活化被阻断。共显微注射的核苷酸和CC使细胞抵抗CC诱导的细胞凋亡在体内,而实验减少核苷酸增强CC和凋亡刺激诱导的细胞死亡。这些观察结果使我们假设,生理水平的核苷酸,除了它们在核酸合成,中间代谢和维持生物能量学中的既定作用外,还通过直接抑制CC介导的溶酶体形成和半胱天冬酶激活来作为关键的促生存因子。有几个关键的未回答的问题有关Apaf-1核糖体的调节核苷酸。我们提出了以下三个具体目标来解决其中的一些问题:1)进一步研究体外核苷酸与CC的相互作用,并阐明体内核苷酸与CC的相互作用; 2)研究核苷酸与Apaf-1的相互作用及其对凋亡体激活的影响;和3)研究Apaf-1亚型表达和核苷酸相互作用对Apaf-1凋亡体激活的影响。这些目标将通过细胞生物学、生物化学和分子方法的组合来实现。所提出的目标的实现将极大地推进我们对体内溶酶体调控的理解,并帮助我们理解细胞对环境应激的反应和癌细胞对抗肿瘤治疗的反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dean G Tang其他文献
12‐Lipoxygenase, 12(S)‐HETE, and Cancer Metastasis a
12-脂氧合酶、12(S)-HETE 和癌症转移
- DOI:
- 发表时间:
1994 - 期刊:
- 影响因子:5.2
- 作者:
Dean G Tang;K. Honn - 通讯作者:
K. Honn
The microRNA miR-34a Inhibits Non-Small Cell Lung Cancer (NSCLC) Growth and the CD44hi Stem-Like NSCLC Cells
- DOI:
doi:10.1371/journal.pone.0090022 - 发表时间:
2014 - 期刊:
- 影响因子:
- 作者:
Yang Shi;Can Liu;Xin Liu;Dean G Tang;Junchen Wang - 通讯作者:
Junchen Wang
Understanding cancer stem cell heterogeneity and plasticity
理解癌症干细胞的异质性和可塑性
- DOI:
10.1038/cr.2012.13 - 发表时间:
2012-01-17 - 期刊:
- 影响因子:25.900
- 作者:
Dean G Tang - 通讯作者:
Dean G Tang
Dean G Tang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dean G Tang', 18)}}的其他基金
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells
联合靶向未分化前列腺癌 (PCa) 干细胞和大量 PCa 细胞的新治疗策略
- 批准号:
9794237 - 财政年份:2019
- 资助金额:
$ 33.68万 - 项目类别:
Correlative efficacy, biomarker, and mechanistic studies associated with a phase Ib/II clinical trial of treating mCRPC patients with enzalutamide and Venetoclax
与恩杂鲁胺和维奈托克治疗 mCRPC 患者的 Ib/II 期临床试验相关的相关疗效、生物标志物和机制研究
- 批准号:
10059185 - 财政年份:2019
- 资助金额:
$ 33.68万 - 项目类别:
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells
联合靶向未分化前列腺癌 (PCa) 干细胞和大量 PCa 细胞的新治疗策略
- 批准号:
10415995 - 财政年份:2019
- 资助金额:
$ 33.68万 - 项目类别:
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells
联合靶向未分化前列腺癌 (PCa) 干细胞和大量 PCa 细胞的新治疗策略
- 批准号:
10164736 - 财政年份:2019
- 资助金额:
$ 33.68万 - 项目类别:
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC
LRIG1 在前列腺癌和 CRPC 中的抑癌功能和分子调控
- 批准号:
10578750 - 财政年份:2019
- 资助金额:
$ 33.68万 - 项目类别:
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells
联合靶向未分化前列腺癌 (PCa) 干细胞和大量 PCa 细胞的新治疗策略
- 批准号:
10631950 - 财政年份:2019
- 资助金额:
$ 33.68万 - 项目类别:
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC
LRIG1 在前列腺癌和 CRPC 中的抑癌功能和分子调控
- 批准号:
10360575 - 财政年份:2019
- 资助金额:
$ 33.68万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 33.68万 - 项目类别: